Dobutamina [Inn-Spanish]
Brand names,
Dobutamina [Inn-Spanish]
Analogs
Dobutamina [Inn-Spanish]
Brand Names Mixture
Dobutamina [Inn-Spanish]
Chemical_Formula
C18H23NO3
Dobutamina [Inn-Spanish]
RX_link
http://www.rxlist.com/cgi/generic3/dobutamine.htm
Dobutamina [Inn-Spanish]
fda sheet
Dobutamina [Inn-Spanish]
msds (material safety sheet)
Dobutamina [Inn-Spanish]
Synthesis Reference
No information avaliable
Dobutamina [Inn-Spanish]
Molecular Weight
301.38 g/mol
Dobutamina [Inn-Spanish]
Melting Point
No information avaliable
Dobutamina [Inn-Spanish]
H2O Solubility
No information avaliable
Dobutamina [Inn-Spanish]
State
Solid
Dobutamina [Inn-Spanish]
LogP
3.489
Dobutamina [Inn-Spanish]
Dosage Forms
Liquid
Dobutamina [Inn-Spanish]
Indication
For inotropic support in the short- term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures
Dobutamina [Inn-Spanish]
Pharmacology
Dobutamine is a direct-acting inotropic agent whose primary activity results from stimulation of the beta-adrenoceptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects. Dobutamine acts primarily on beta-1 adrenergic receptors, with little effect on beta-2 or alpha receptors. It does not cause the release of endogenous norepinephrine, as does dopamine. Dobutamine is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures.
Dobutamina [Inn-Spanish]
Absorption
No information avaliable
Dobutamina [Inn-Spanish]
side effects and Toxicity
No information avaliable
Dobutamina [Inn-Spanish]
Patient Information
No information avaliable
Dobutamina [Inn-Spanish]
Organisms Affected
Humans and other mammals